Q&A: Blood disorder causes body to make too many red blood cells

Credit: CC0 Public Domain

DEAR MAYO CLINIC: I have a relative who was diagnosed with polycythemia vera. What is this disorder, and can it be treated? Is any new research being conducted on polycythemia vera?

ANSWER: Polycythemia vera is a where the body makes too many . It's one in a family of diseases called myeloproliferative disorders. In these diseases, bone marrow—the spongy tissue inside bones where are made—is affected by a type of chronic leukemia that causes it to make more than it should.

Patients with polycythemia vera have a high red blood cell count. But sometimes the disease also can result in too many , or too many platelets—the component of blood that aids in clotting. A considerable amount of research is underway to investigate this blood disorder and treatments for it.

Exactly why polycythemia vera develops is still unclear, although researchers know more about the cause of the disease now than in the past. In 2005, researchers found that a change in a gene that affects the protein JAK2 appears to play a role in polycythemia vera development.

JAK2 is one in a series of on/off switches that control when cells grow and divide. In polycythemia vera, this switch is stuck in the on position, causing cell growth to continue. About 95% of people with polycythemia vera have the JAK2 mutation. The others have different mutations that are thought to affect cells similarly. Research is ongoing.

In its early stages, polycythemia vera may not cause symptoms. Due to the excess red blood cells, though, some people may eventually develop skin itchiness and redness; headaches; dizziness; shortness of breath; and numbness, tingling, burning or weakness in their hands, feet, arms or legs. Because polycythemia vera causes blood to thicken and slow, it also can increase the risk of developing blood clots, which can cause a stroke.

Over the long term, polycythemia vera may progress to myelofibrosis, a disorder that involves scarring in the bone marrow and disruption of the production of blood cells, and it can lead to enlargement of the spleen and liver. Polycythemia vera also can progress to acute leukemia, a cancer of the blood and bone marrow.

Treatment of polycythemia vera focuses on controlling symptoms and decreasing the risk of blood clots or bleeding. Therapies often include a daily dose of aspirin and reducing the amount of red blood cells by periodically drawing blood from a vein.

In some , medication may be used to decrease the number of red blood cells or to suppress the bone marrow's ability to produce blood cells. People who require medication typically include those older than 60, people who have previously had blood clots or bleeding, people who are at high risk of heart disease, and those with significantly elevated platelet counts.

The three main drugs used to treat polycythemia vera and lower blood counts have been hydroxyurea, peginterferon alfa-2a and ruxolitinib. Hydroxyurea is the typical first therapy, as it works well and has the least side effects. Ruxolitinib is unique in that it targets the JAK2 mutation directly. The most recently approved drug is ropeginterferon alpha 2b-njft. It was approved in November 2021. It also works to reduce red cell production and decrease the risk of . Patients who progress to myelofibrosis or acute leukemia may need chemotherapy, a stem cell transplant or both to treat the disease.

Over 250 are being conducted on . The research includes new drugs, as well as therapies for controlling symptoms and reducing the risk of progression to myelofibrosis and acute leukemia.—Dr. Marwan Shaikh, Hematology/Oncology, Mayo Clinic, Jacksonville, Florida

Explore further

Gene mutations and the clinical presentation of myeloproliferative neoplasms

2022 Mayo Clinic News Network.
Distributed by Tribune Content Agency, LLC.

Citation: Q&A: Blood disorder causes body to make too many red blood cells (2022, April 13) retrieved 1 July 2022 from https://medicalxpress.com/news/2022-04-qa-blood-disorder-body-red.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors